Senescence drives immunotherapy resistance by inducing an immunosuppressive tumor microenvironment
Top Cited Papers
Open Access
- 18 March 2024
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-15
Abstract
The potential of immune checkpoint inhibitors (ICI) may be limited in situations where immune cell fitness is impaired. Here, we show that the efficacy of cancer immunotherapies is compromised by the accumulation of senescent cells in mice and in the context of therapy-induced senescence (TIS). Resistance to immunotherapy is associated with a decrease in the accumulation and activation of CD8 T cells within tumors. Elimination of senescent cells restores immune homeostasis within the tumor micro-environment (TME) and increases mice survival in response to immunotherapy. Using single-cell transcriptomic analysis, we observe that the injection of ABT263 (Navitoclax) reverses the exacerbated immunosuppressive profile of myeloid cells in the TME. Elimination of these myeloid cells also restores CD8 T cell proliferation in vitro and abrogates immunotherapy resistance in vivo. Overall, our study suggests that the use of senolytic drugs before ICI may constitute a pharmacological approach to improve the effectiveness of cancer immunotherapies.Keywords
All Related Versions
Funding Information
- Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre (PJT-169017)
- Cancer Research Society (CRP-159385)
This publication has 63 references indexed in Scilit:
- Cancer cell-derived type I interferons instruct tumor monocyte polarizationCell Reports, 2022
- PGE2-EP2/EP4 signaling elicits immunosuppression by driving the mregDC-Treg axis in inflammatory tumor microenvironmentCell Reports, 2022
- Heterochronic parabiosis induces stem cell revitalization and systemic rejuvenation across aged tissuesCell Stem Cell, 2022
- Autologous humanized mouse models of iPSC-derived tumors enable characterization and modulation of cancer-immune cell interactionsCell Reports Methods, 2022
- Efficacy of immune checkpoint inhibitors in older patients with non-small cell lung cancer: Real-world data from multicentric cohorts in Canada and FranceJournal of Geriatric Oncology, 2020
- Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor modelsCancer Immunology, Immunotherapy, 2020
- Fisetin is a senotherapeutic that extends health and lifespanEBioMedicine, 2018
- Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint BlockadeCell, 2016
- An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AADevelopmental Cell, 2014
- Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediatedInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2004